| Dr David John Hanson, PHARMD | |
|
12122 State Line Rd, Leawood, KS 66209-1254 | |
| (913) 345-9377 | |
| Not Available |
| Full Name | Dr David John Hanson |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 12122 State Line Rd, Leawood, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174067474 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 11217 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David John Hanson, PHARMD 12855 Sagamore Rd, Leawood, KS 66209-1633 Ph: (913) 269-2640 | Dr David John Hanson, PHARMD 12122 State Line Rd, Leawood, KS 66209-1254 Ph: (913) 345-9377 |
News Archive
Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute.
A new study shows a person's stroke risk profile, which includes high blood pressure, smoking, and diabetes, may also be helpful in predicting whether a person will develop memory and thinking problems later in the life.
Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Transplanting fat may treat such inherited metabolic diseases as maple syrup urine disease (MSUD) by helping the body process the essential amino acids that these patients cannot, according to Penn State College of Medicine researchers.
Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.
› Verified 3 days ago
Dr. Jack R Bates, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9521 Mission Rd, Leawood, KS 66206 Phone: 913-383-2823 | |
Catherine Khalil, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4701 Town Center Dr, Leawood, KS 66211 Phone: 913-469-4014 | |
Mary K Wilson, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2305 W 123rd Ter, Leawood, KS 66209 Phone: 816-588-2215 | |
Ines Fomaga Tsotezo, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8316 Overbrook Rd, Leawood, KS 66206 Phone: 316-768-0098 | |
Tiana Williams, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5001 W 135th St, Leawood, KS 66224 Phone: 913-851-9903 | |
Dr. Jason S Kim, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12724 Sagamore Rd, Leawood, KS 66209 Phone: 858-220-2615 |